Aligos Therapeutics (ALGS)

• Market cap: $31.9M
• 1 day: -5.33%
• 5 days: -10.75%
• 1 month: -9.49%
• 3 months: -20.89%
• 6 months: -39.7%
• Year to date: -43.59%
• 1 year: -43.53%
• 5 years: -98.69%
• 10 years: -98.61%
• Sector: Healthcare
• Industry: Biotechnology

About: Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Employees: 82